AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement [Seeking Alpha]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Seeking Alpha
ANAB plans to advance rosnilimab for RA, with a program update expected in the first half of 2026, seeking non-dilutive funding or a strategic partner. Development of CD122 antagonist ANB033 for Celiac Disease continues in phase 1b, targeting a large unmet market with a clinically validated approach from several other companies with IL-15/CD122 targeting. Despite financial risks and competition, ANAB's cash position and ongoing programs support maintaining a "Hold" rating pending key 2026 catalysts. Ashi Sae Yang/iStock via Getty Images The last time I spoke about AnaptysBio ANAB ), it was with respect to a Seeking Alpha article entitled " AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement ". Since More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- SA Quant ranks Goldman's small-cap stocks with largest short interest [Seeking Alpha]Seeking Alpha
- Anaptys Announces Participation in December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Anaptys Announces Participation in December Investor ConferencesGlobeNewswire
- AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $50.00 price target on the stock.MarketBeat
- AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $52.00 to $51.00. They now have a "buy" rating on the stock.MarketBeat
ANAB
Earnings
- 11/4/25 - Beat
ANAB
Sec Filings
- 11/26/25 - Form 8-K
- 11/21/25 - Form 8-K
- 11/21/25 - Form 8-K
- ANAB's page on the SEC website